Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 3 (2006), Issue 10 (October)

1. Dosimetric verification for intensity-modulated radiotherapy of thoracic cancers using experimental and Monte Carlo approaches.
   Int J Radiat Oncol Biol Phys, 66(3): 939-48. [Abstract] [Full-text]
2. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study.
   Int J Radiat Oncol Biol Phys, 66(3): 748-53. [Abstract] [Full-text]
3. Benefit of three-dimensional image-guided stereotactic localization in the hypofractionated treatment of lung cancer.
   Int J Radiat Oncol Biol Phys, 66(3): 738-47. [Abstract] [Full-text]
4. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.
   Int J Cancer, 119(10): 2353-8. [Abstract] [Full-text]
5. Optimal number of beams for stereotactic body radiotherapy of lung and liver lesions.
   Int J Radiat Oncol Biol Phys, 66(3): 906-12. [Abstract] [Full-text]
6. Physical activity and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition Cohort.
   Int J Cancer, 119(10): 2389-97. [Abstract] [Full-text]
7. Lung cancer risk among US radiologic technologists, 1983-1998.
   Int J Cancer, 119(10): 2481-6. [Abstract] [Full-text]
8. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer.
   Br J Cancer, 95(7): 817-21. [Abstract] [Full-text]
9. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer.
   Br J Cancer, 95(7): 822-8. [Abstract] [Full-text]
10. Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer.
    Am J Clin Oncol, 29(5): 503-7. [Abstract] [Full-text]
11. Bronchial malondialdehyde DNA adducts, tobacco smoking, and lung cancer.
    Free Radic Biol Med, 41(9): 1499-505. [Abstract] [Full-text]
12. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal.
    Free Radic Biol Med, 41(9): 1449-58. [Abstract] [Full-text]
13. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    J Clin Oncol, 24(29): 4721-30. [Abstract] [Full-text]
14. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
    J Clin Oncol, 24(29): 4731-7. [Abstract] [Full-text]
15. Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells.
    Cancer Lett, 242(2): 231-8. [Abstract] [Full-text]
16. Metastases to the pineal gland.
    Neurology, 67(7): 1303-4. [Abstract] [Full-text]
17. Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.
    Genes Chromosomes Cancer, 45(12): 1094-105. [Abstract] [Full-text]
18. Functional analysis of lung tumor suppressor activity at 3p21.3.
    Genes Chromosomes Cancer, 45(12): 1077-93. [Abstract] [Full-text]
19. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
    J Clin Oncol, 24(30): 4848-54. [Abstract] [Full-text]
20. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    J Clin Oncol, 24(30): 4840-7. [Abstract] [Full-text]
21. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
    J Clin Oncol, 24(30): 4833-9. [Abstract] [Full-text]
22. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
    J Clin Oncol, 24(30): 4825-32. [Abstract] [Full-text]
23. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
    J Clin Oncol, 24(30): 4818-24. [Abstract] [Full-text]
24. Retrospective mortality cohort study of Italian workers compensated for silicosis.
    Occup Environ Med, 63(11): 762-5. [Abstract] [Full-text]
25. Occupational exposure to eight organic dusts and respiratory cancer among Finns.
    Occup Environ Med, 63(11): 726-33. [Abstract] [Full-text]
26. Pax-5 expression in nonhematopoietic tissues.
    Am J Clin Pathol, 126(5): 798-804. [Abstract] [Full-text]
27. Small pulmonary nodules: effect of two computer-aided detection systems on radiologist performance.
    Radiology, 241(2): 564-71. [Abstract] [Full-text]
28. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
    AJR Am J Roentgenol, 187(5): 1361-7. [Abstract] [Full-text]
29. Ventilation-perfusion scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing pneumonectomy.
    AJR Am J Roentgenol, 187(5): 1260-5. [Abstract] [Full-text]
30. Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements.
    Radiology, 241(2): 554-63. [Abstract] [Full-text]
31. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Radiology, 241(2): 501-9. [Abstract] [Full-text]
32. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
    J Thorac Cardiovasc Surg, 132(5): 1189-95. [Abstract] [Full-text]
33. Electromagnetic navigation diagnostic bronchoscopy: a prospective study.
    Am J Respir Crit Care Med, 174(9): 982-9. [Abstract] [Full-text]
34. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers.
    Mol Carcinog, 45(11): 828-32. [Abstract] [Full-text]
35. Pharmacokinetics and toxicity of weekly docetaxel in older patients.
    Clin Cancer Res, 12(20): 6100-5. [Abstract] [Full-text]
36. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
    Clin Cancer Res, 12(20): 6049-55. [Abstract] [Full-text]
37. Usefulness of lung perfusion scintigraphy before lung cancer resection in patients with ventilatory obstruction.
    Ann Thorac Surg, 82(5): 1828-34. [Abstract] [Full-text]
38. Video-assisted mediastinoscopic surgery: clinical feasibility and accuracy of mediastinal lymph node staging.
    Ann Thorac Surg, 82(5): 1821-7. [Abstract] [Full-text]
39. Radioguided detection of lymph node metastasis in non-small cell lung cancer.
    Ann Thorac Surg, 82(5): 1815-20; discussion 1820. [Abstract] [Full-text]
40. Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer.
    Ann Thorac Surg, 82(5): 1808-13; discussion 1813-4. [Abstract] [Full-text]
41. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma.
    Ann Thorac Surg, 82(5): 1802-7. [Abstract] [Full-text]
42. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Clin Cancer Res, 12(20): 6079-86. [Abstract] [Full-text]
43. Survival of patients with stage I lung cancer detected on CT screening.
    N Engl J Med, 355(17): 1763-71. [Abstract] [Full-text]
44. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung.
    Int J Cancer, 119(11): 2603-6. [Abstract] [Full-text]
45. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
    Int J Cancer, 119(11): 2546-56. [Abstract] [Full-text]
46. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
    Int J Cancer, 119(11): 2586-91. [Abstract] [Full-text]
47. Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells.
    Oncogene, 25(50): 6672-7. [Abstract] [Full-text]
48. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment.
    Gynecol Oncol, 103(2): 479-82. [Abstract] [Full-text]
49. Determinants of quality of life in patients following pulmonary resection for lung cancer.
    Am J Surg, 192(5): 565-71. [Abstract] [Full-text]
50. Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.
    Invest New Drugs, 25(1): 57-62. [Abstract] [Full-text]
51. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.
    J Clin Oncol, 24(31): 5079-90. [Abstract] [Full-text]
52. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    J Clin Oncol, 24(31): 5034-42. [Abstract] [Full-text]
53. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
    J Clin Oncol, 24(31): 5025-33. [Abstract] [Full-text]
54. Transactivation of the proximal promoter of human oxytocin gene by TR4 orphan receptor.
    Biochem Biophys Res Commun, 351(1): 204-8. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.